Fulcrum Therapeutics, Inc.

How big is Fulcrum Therapeutics, Inc.?

As of Jun 18, Fulcrum Therapeutics, Inc. has a market capitalization of 347.09 million, with net sales of 80.00 million and a net profit of -0.52 million over the latest four quarters. The company reported shareholder's funds of 243.03 million and total assets of 260.72 million as of Dec 24.

Market Cap: As of Jun 18, Fulcrum Therapeutics, Inc. has a market capitalization of 347.09 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Fulcrum Therapeutics, Inc. reported net sales of 80.00 million and a net profit of -0.52 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 243.03 million and total assets of 260.72 million.

What does Fulcrum Therapeutics, Inc. do?

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on treating genetically defined rare diseases. As of March 2025, it has a market cap of $347.09 million and reported a net profit of -$18 million.

Overview: <BR>Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -18 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 347.09 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 252.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.98 <BR>Return on Equity: 0.68% <BR>Price to Book: 1.52<BR><BR>Contact Details: <BR>Address: 26 Landsdowne St, CAMBRIDGE MA: 02139-4216 <BR>Tel: ['1 617 6518851', '1 212 3621200'] <BR>Fax: 1 302 6555049 <BR>Website: http://www.fulcrumtx.com/

Should I buy, sell or hold Fulcrum Therapeutics, Inc.?

Who are in the management team of Fulcrum Therapeutics, Inc.?

As of March 2022, the management team of Fulcrum Therapeutics, Inc. includes Mr. Mark Levin (Independent Chairman), Dr. Robert Gould (President and CEO), and several Independent Directors: Dr. James Collins, Ms. Katina Dorton, Dr. Alan Ezekowitz, Mr. James Geraghty, and Ms. Kate Haviland.

As of March 2022, the management team of Fulcrum Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Mark Levin, who serves as the Independent Chairman of the Board.<BR>- Dr. Robert Gould, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. James Collins, who is an Independent Director.<BR>- Ms. Katina Dorton, who is an Independent Director.<BR>- Dr. Alan Ezekowitz, who is an Independent Director.<BR>- Mr. James Geraghty, who is an Independent Director.<BR>- Ms. Kate Haviland, who is an Independent Director. <BR><BR>This team comprises a mix of executive leadership and independent directors contributing to the governance of the company.

Is Fulcrum Therapeutics, Inc. overvalued or undervalued?

As of July 29, 2025, Fulcrum Therapeutics, Inc. is considered overvalued with a high P/E ratio of 252 and negative EV to EBIT and EV to EBITDA ratios, indicating a significant decline in investment appeal despite a recent 60.43% year-to-date return.

As of 29 July 2025, the valuation grade for Fulcrum Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears overvalued, particularly when considering its P/E ratio of 252, which is substantially higher than typical industry benchmarks, and a PEG ratio of 2.48, suggesting that the stock is priced high relative to its expected growth. Additionally, the negative EV to EBIT and EV to EBITDA ratios of -16.05 and -18.80 further highlight the company's struggles in generating earnings relative to its enterprise value.<BR><BR>In comparison to its peers, KalVista Pharmaceuticals, Inc. has a P/E of -4.3845 and MacroGenics, Inc. has a P/E of -3.0562, both reflecting a more favorable valuation relative to Fulcrum. Despite a strong year-to-date return of 60.43% compared to the S&P 500's 12.22%, the long-term performance shows a decline of 14.71% over three years, indicating that the recent gains may not be sustainable. Overall, Fulcrum Therapeutics is currently overvalued based on the provided metrics.

Is Fulcrum Therapeutics, Inc. technically bullish or bearish?

As of July 30, 2025, Fulcrum Therapeutics, Inc. has a mildly bullish trend, supported by a bullish daily moving average and monthly Bollinger Band, despite some caution from weekly MACD and KST indicators, while significantly outperforming the S&P 500 with a 1-year return of 119.19% compared to 17.14%.

As of 30 July 2025, the technical trend for Fulcrum Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish daily moving average and a bullish monthly Bollinger Band. However, the weekly MACD and KST indicators are mildly bearish, indicating some caution. <BR><BR>In terms of performance, the company has shown strong returns, outperforming the S&P 500 significantly with a 1-year return of 119.19% compared to the S&P's 17.14%, and a year-to-date return of 60.43% against the S&P's 12.22%.